All In Biotech

Drug Trial Radar · NCT03729245

A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined With Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients With Previously Untreated Advanced Renal Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Apr 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 623 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

623

Actual

Start

Dec 18, 2018

Primary completion

Jan 7, 2022

Study completion Oct 19, 2022

Sponsor

Lead sponsor
Nektar TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Bristol-Myers Squibb
First posted
Nov 2, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to compare the objective response rate (ORR) and overall survival (OS) of bempegaldesleukin (NKTR-214: BEMPEG) combined with nivolumab to that of tyrosine kinase inhibitor (TKI) monotherapy (sunitinib or cabozantinib) in IMDC intermediate- or poor-risk patients and IMDC all-risk patients with previously untreated advanced renal cell carcinoma (RCC).

Conditions

  • Renal Cell Carcinoma
  • Metastatic Renal Cell Carcinoma

Interventions

  • bempegaldesleukinBiological

    Specified dose on specified days

  • sunitinibDrug

    Specified dose on specified days

  • nivolumabBiological

    Specified dose on specified days

  • cabozantinibDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) Per mRECIST 1.1 by BICR in IMDC All-risk Patients and Intermediate- or Poor (I/P)-Risk Patients With Previously Untreated Advanced RCCTime frame: Approximately 32 months
  2. Overall Survival (OS) in IMDC All-Risk and Intermediate- or Poor-risk Patients With Previously Untreated Advanced RCCTime frame: Approximately 32 months

Locations

96 sites in 10 countries. Site status is shown where the registry gives one.

  • Alaska Urological

    Anchorage, Alaska

  • Western Regional Medical Center - CTCA - PPDS

    Goodyear, Arizona

  • CARTI Cancer Center

    Little Rock, Arkansas

  • City of Hope National Medical Center

    Duarte, California

  • University of California Irvine

    Orange, California

  • Innovative Clinical Research Institute

    Whittier, California

  • University of Miami

    Miami, Florida

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia

  • Tulane Medical Center

    New Orleans, Louisiana

  • University of Maryland Greenebaum Cancer Center

    Baltimore, Maryland

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • North Shore Hematology Oncology Association PC

    Port Jefferson Station, New York

  • Kettering Medical Center

    Kettering, Ohio

  • Providence Cancer Institute, Franz Clinic

    Portland, Oregon

  • Lehigh Valley Physician Group (LVPG) - Hematology Oncology

    Allentown, Pennsylvania

  • Penn State Milton S Hershey Medical Center

    Hershey, Pennsylvania

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Eastern Regional Medical Center - CTCA

    Philadelphia, Pennsylvania

  • MD Anderson Cancer Center

    Houston, Texas

  • Huntsman Cancer Hospital - PPDS

    Salt Lake City, Utah

  • Centro de Investigación Pergamino S.A

    Buenos Aires, Argentina

  • Centro Médico Austral

    Buenos Aires, Argentina

  • Instituto Médico Especializado Alexander Fleming

    Buenos Aires, Argentina

  • Centro Médico Privado CEMAIC

    Córdoba, Argentina

  • Sanatorio Allende S.A.

    Córdoba, Argentina

  • Sanatorio Privado Duarte Quirós, de Clínica Colombo S.A.

    Córdoba, Argentina

  • Centro Oncologico Riojano Integral (cori)

    La Rioja, Argentina

  • Hospital Provincial Del Centenario

    Rosario, Argentina

  • CAIPO Centro para la atención integral del paciente oncológico

    San Miguel de Tucumán, Argentina

  • Sanatorio Parque de Rosario

    Santa Fe, Argentina

  • Centro de Investigación Clínica - Clínica Viedma

    Viedma, Río Negro Province, Argentina

  • Orange Cancer Centre

    Orange, New South Wales, Australia

  • Royal North Shore Hospital

    Saint Leonards, New South Wales, Australia

  • Macquarie University

    Sydney, New South Wales, Australia

  • Adelaide Cancer Centre

    Kurralta Park, South Australia, Australia

  • Barwon Health

    Parkville, Victoria, Australia

  • Instituto de Pesquisas Clínicas Para Estudos Multicêntricos

    Caxias do Sul, Brazil

  • Instituto Do Câncer Do Ceará ICC

    Fortaleza, Brazil

  • Animi

    Lages, Brazil

  • Instituto Nacional de Câncer

    Rio de Janeiro, Brazil

Showing 40 of 96 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.